IPO-bound Corona Remedies has acquired one cardiology and six women’s healthcare brands from the pharmaceutical division of Bayer in India.
The acquisition of Noklot brand marks its entry into the anti-platelet monotherapy segment, which is valued at ₹1,507 crore and growing at 8%. The acquired women’s healthcare portfolio comprising Fostine, Luprofact, Menodac, Ovidac, Spye and Vageston will enhance its presence in the Gonadotrophin and Progesterone Hormone market, which stood at ₹1,862 crore, Ahmedabad-based Corona Remedies said citing MAT June 2025 numbers.
The acquisition is effective July 16, the company said without sharing the financials of the transaction. It said the latest acquisition is the fourth from multinational corporations. Sanofi, GlaxoSmithKline and Abbott India were the companies from which it had acquired brands earlier.
Corona Remedies had filed Draft Red Herring Prospectus (DRHP), for an initial public offering, with SEBI in April.
Published – July 17, 2025 10:17 pm IST
